HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the State Intellectual Property Office of the People's Republic of China ("SIPO") successfully completed a preliminary review of the Company's patent application for its advanced proprietary Schisandra Lignin Extraction Method.
Research in China suggests that Schisandra, a wild plant with high medicinal and health benefits, has a protective effect on the liver and is effective as a sedative for treating insomnia and central nervous system depression. Lignin compounds have been shown as a good source of powerful anti-oxidants with promising benefits in fighting major conditions, including HIV, cancer and high blood pressure. Renhuang's proprietary Schisandra lignin extraction method enables the Company to obtain higher purity of lignin from the plant, which may substantially enhance the efficacy of medicines produced from these compounds. The Company's patent application has now entered the SIPO comprehensive examination phase, which is typically a two year process. If approved by the SIPO, the patent will provide Renhuang market exclusivity for its Schisandra-based products for a period of 16 to 18 years.
"We are pleased that our advanced proprietary Schisandra Lignin Extraction Method patent application has passed an important stage in the patent approval process," said Mr. Shaoming Li, Chairman and CEO of Renhuang Pharmaceuticals, Inc. "We continue to strive towards securing patents on our unique proprietary extraction methods, which is an important part of our long-term growth strategy. The successful development of our high-quality, proprietary extraction method provides a strong foundation for advancing the development of Schisandra based products and is expected to strengthen our competitive edge during the commercialization of the product in the future."
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com .
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to secure and enforce patent rights for its proprietary extraction methods, successfully develop and commercialization of its Schisandra-based drugs, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-5392-5461 Email: email@example.com CCG Investor Relations: Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: firstname.lastname@example.org Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: email@example.com Web: http://www.ccgirasia.com
|SOURCE Renhuang Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved